Articles On Invion (ASX:IVX)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX rises +0.5% before sliding back to just +0.18% Broad strength overall, however, with eight sectors higher Soft GDP numbers hide robust economic indicators   ASX slows to a flattish finish The ASX 200 took a sharp dip into negative ter...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

ASX down 9 points as AI jitters and profit taking set in Healthcare, materials sectors limit losses with some solid gains PainChek and Neurotech grab headlines with FDA wins; Dimerix also gains on strong news Glencore Mt Isa smelter bailed...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

ASX shifts gears around 11am to lift 0.25pc by end of trade Banks, discretionary and real estate lead gains Materials drags as James Hardie dives   ASX settles back into green Earnings season is making for a bit of a seesaw on the ASX thi...

The ASX200 has pared early losses trading flattish green leading into close. Real Estate was the dominant sector dragging the index higher, followed by Discretionary and Utilities. Across the ditch, New Zealand’s Reserve Bank cut the kiw...

CSL shares have taken another 8% bath, even though brokers maintain valuations well above the current level Aroa Biosurgery says growing non-US sales should offset the impact of Trumpian tariffs “Opthea 2.0” is likely to stick with its kni...

  In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several compa...

ASX bulls take a breath as market falls 0.7pc Healthcare leads losses, down 8.7pc Biotech heavyweight CSL suffers worst single day losses in decades   Healthcare sector in need of resuscitation The ASX has given up its bull rush for the m...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Energy sector pushes ASX 0.15pc higher US court has ruled Trump’s Liberation Day and fentanyl tariffs are unlawful Steel, aluminium and auto tariffs remain in place   The ASX has posted another gain today, albeit a small 0.15% lift. News...

Highlights ASX 200 edges higher as energy and tech sectors lead early gains Invion (ASX:IVX) updates trial results for non-melanoma skin cancer treatment EU-US trade talks continue, impacting sentiment across global indices...

Invion (ASX: IVX) has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland. Data from a safety review committ...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully breaks down the latest scoop from Invion (ASX:IVX), which has achieved a major milestone in its Phase I/II clinical trai...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Biotech company Invion Ltd (ASX:IVX) is raising $2 million in a two-tranche share placement to support a series of clinical trials and development activities for its Photosoft technology, seeking to treat a range of cancers. The company...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

A number of ASX-listed healthcare companies, many with relatively low market caps, are making strides in tackling cancer Imagion is  aiming to revolutionise cancer diagnosis by introducing molecular imaging to magnetic resonance imaging (M...

The S&P/ASX 200 rose 5% in January to reach a new record high Utilities was the only sector to fall in January with financials the top performer AusQuest tops January winners up 388% with discovery of a large-scale Peruvian copper pros...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

This week’s Bulls N’ Bears Runner of the Week is … Aldoro Resources. The Namibian explorer stacked on 201% after jagging niobium in trenching samples, while Macro Metals, Invion and Petratherm also ran hard.

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX hits record high, driven by consumer stocks Zip co-founder steps down, Collins Foods drops Invion doubles after commencing phase I/II trial    The ASX hit a new record on Tuesday, marking its third all-time high in just a week.  At th...

Investors in ASX small-cap stock Invion Ltd (ASX: IVX) could have doubled their money today. All in a few hours' time. Shares in the ASX healthcare company closed yesterday trading for 18 cents. In earlier trade, shares were trading for 41....

Invion enrols its first patient in its Queensland skin cancer study Inoviq says it has the clinical proof to commercialise its early-stage ovarian cancer detection test Are we on the cusp of Trump-driven US healthcare M&A fiesta?   I...

Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer (NMSC) trial using active pharmaceutical ingredient and lead candidate INV043. The trial will aim to evaluate the...

  Thian Chew – Executive Chair and CEO – Invion Limited (ASX:IVX) is a clinical-stage life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclero...

ASX hits record high with tech stocks leading TechnologyOne shares soar after strong earnings results Gold stocks rally as bullion rises above US$2600   The ASX surged to a new record on Monday, with technology and the other 10 sectors dr...

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership   The ASX kicked off November with a thud, sliding about 0.5%. This  follows a tough session o...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

  ASX slumps heavily after inflation data Australian inflation drops to 2.8pc, lower than expected Mining stocks rise while supermarket stocks struggle   The ASX trimmed its earlier gains following better-than-expected inflation figures....

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX edges slightly up by 0.12pc as traders rethink rate cuts Consumer staples shine while gold miners gain amid global tensions 29Metals plunges after cash reserve drop and production decline   The ASX ticked up higher by 0.1% on Wednesd...

  The ASX fell on new expectations for rate cuts All 11 ASX sectors fell, with real estate and healthcare hit hardest MinRes and Viva Energy dropped, Prodigy Gold rose 50pc   The ASX slid by 1.66% from near record highs in a broad sell-o...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

  ASX 200 hits record highs fuelled by Wall Street rally Tech and iron ore stocks lead gains Tyro sinks after government proposes new rules on debit surcharge   The ASX 200 index hit record highs on Tuesday after rising by 0.9%, eclipsin...

Highlights ASX 200 hits new record as InfoTech and Telcos lead early trading. Crude oil weakness impacts Woodside and Santos. Small-cap stocks Nanoveu and African Gold post strong gains. The ASX 200 opened on a high note today, bu...

ASX fell as mining stocks dropped on China’s lack of stimulus Brent oil dipped below US$80 Big lithium stocks fall, but smaller players keep gaining after Rio Tinto’s Arcadium takeover talks   The ASX closed lower by 0.35% in a volatile...